Related Experiment Video
Updated: Feb 4, 2026
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
2.1K
Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction
1Department of Medicine, Section of Cardiology, Baylor College of Medicine, 6620 Main Street, 12th Floor, Suite 1225, Houston, TX 77030, USA.
Heart Failure Clinics
|September 30, 2018
Summary
Heart failure with preserved ejection fraction (HFpEF) affects over half of heart failure patients. Current treatments lack proven mortality benefits, highlighting the need for further research into HFpEF therapies.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Over 50% of clinical heart failure cases involve preserved ejection fraction (HFpEF).
- HFpEF carries mortality rates comparable to heart failure with reduced ejection fraction.
- Existing therapeutic trials have failed to demonstrate a mortality benefit for HFpEF.
Purpose of the Study:
- To review the challenges and potential therapeutic avenues for heart failure with preserved ejection fraction (HFpEF).
- To explore the reasons behind the lack of demonstrated treatment efficacy in HFpEF clinical trials.
Main Methods:
- Review of existing clinical trial data for heart failure with preserved ejection fraction (HFpEF).
- Analysis of factors contributing to trial heterogeneity, including patient selection and medication adherence.
- Evaluation of potential therapeutic strategies, such as mineralocorticoid receptor antagonists.
Main Results:
- No therapy has shown a significant mortality benefit in large clinical trials for HFpEF to date.
- The heterogeneity and complex pathophysiology of HFpEF may explain the negative trial outcomes.
- Geographic variations and adherence issues complicate trial result interpretation.
Conclusions:
- Heart failure with preserved ejection fraction (HFpEF) remains a therapeutic challenge.
- Mineralocorticoid receptor antagonists show promise in specific HFpEF patient subgroups.
- Further research is needed to address the complex nature of HFpEF and identify effective treatments.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
948
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
948
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
01:22Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
01:22Heart Failure Drugs: Diuretics
981
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
981
01:30Heart Failure V: Medical Management
329
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
329